Boston Scientific Parkinson's DBS treatment wins CE mark

Boston Scientific ($BSX) gained a CE mark for its Vercise deep brain stimulation system as a Parkinson's disease treatment. It uses electrical signals on specific areas of the brain to address Parkinson's symptoms. The Natick, MA-based device company bills its system as the first on the commercial market able to use multiple independent current control. Vercise could reach an enormous amount of Parkinson's patients; as many as 6.3 million people globally, according to data Boston Scientific cites from the European Parkinson's Disease Association. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.